Observational studyBMC cardiovascular disorders2025
Association between cardiometabolic comorbidity and mortality in patients with atrial fibrillation.
Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-Term Cardiovascular and Mortality Risk in Patients with Pre-Existing Arrhythmia Post-SARS-CoV-2 Infection.Diagnostics (Basel, Switzerland) · 2025Article
- Alkaline Phosphatase to Albumin Ratio as a Novel Predictor of All-Cause Mortality in Critically Ill Patients With Atrial Fibrillation.Cardiology research and practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPatients with atrial fibrillation (AF) often suffer from cardiometabolic comorbidities, but the impact of the type and number of cardiometabolic comorbidities on the prognosis of AF patients remain unclear.
methodsFrom August 2011 to December 2018, 23,838 AF patients from the Chinese Atrial Fibrillation Registry (China-AF) Study were enrolled in this study. The all-cause and cardiovascular-cause mortality was described. The Cox proportional hazard model was employed to explore the associations of the type and number of cardiometabolic comorbidities with all-cause and cardiovascular-cause mortality.
resultsDuring an average follow-up of 4.07 ± 1.96 years, 2,140 (8.98%) deaths were identified. The mortality in AF patients with cardiometabolic conditions was significantly higher than that in AF patients without cardiometabolic conditions. Cardiovascular events contributed the most to the death of AF patients, particularly heart failure. AF complicated with heart failure was associated with the highest risk of all-cause mortality [hazard ratio (HR) 1.92, 95% confidence interval (CI) 1.74-2.13], followed by thromboembolism, diabetes mellitus, and vascular diseases. Whereas, the presence of co-morbid hypertension did not have a significant association with all-cause mortality (HR 0.97, 95%CI 0.86-1.09). The adjusted HRs for all-cause mortality in AF patients were 1.21 (95%CI 0.99-1.47), 1.71 (95%CI 1.40-2.08), 2.55 (95%CI 2.07-3.13), and 3.39 (95%CI 2.71-4.24) for 1, 2, 3, and ≥ 4 cardiometabolic comorbidities, respectively.
conclusionThe increase in the number of cardiometabolic comorbidities is associated with mortality in AF patients. Hence, strengthening the management of cardiometabolic comorbidities is critical to reducing the mortality of patients with AF.
trial registrationURL: http://www.chictr.org.cn/showproj.aspx?proj=5831 . REGISTRATION NUMBER: ChiCTR-OCH-13003729. Date of the registration is October 22, 2013.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.